Showing results (141-150 of 279) with videos related to
Sort By:
Pageof 28
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.Cancer Cell|April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitorsIfat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2022
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based AnalysisJohannes Lübke, Juliana Schwaab, Nicole Naumann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2017
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With MyelofibrosisRuben A Mesa, Jean-Jacques Kiladjian, John V Catalano, et al.Blood Advances|January 31, 2018
Variability of PD-L1 expression in mastocytosisEllen W Hatch, Mary Beth Geeze, Cheyenne Martin, et al.Science Translational Medicine|February 18, 2010
Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencingScott D Boyd, Eleanor L Marshall, Jason D Merker, et al.Haematologica|June 13, 2015
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M Vannucchi, Hagop M Kantarjian, Jean-Jacques Kiladjian, et al.Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.Clinical Pharmacology and Therapeutics|August 21, 2024
Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape AnalysisChristina M Lockwood, Jason D Merker, Elizabeth Bain, et al.Pageof 28